MCID: THR005
MIFTS: 63

Thrombotic Thrombocytopenic Purpura

Categories: Rare diseases, Blood diseases, Nephrological diseases, Genetic diseases

Aliases & Classifications for Thrombotic Thrombocytopenic Purpura

MalaCards integrated aliases for Thrombotic Thrombocytopenic Purpura:

Name: Thrombotic Thrombocytopenic Purpura 12 24 36 14 59
Purpura, Thrombotic Thrombocytopenic 72 24 41 69
Microangiopathic Hemolytic Anemia 24 69
Congenital Thrombotic Thrombocytopenic Purpura 69
Familial Thrombotic Thrombocytopenia Purpura 24
Familial Thrombotic Thrombocytopenic Purpura 69
Thrombotic Microangiopathy, Familial 24
Purpura Thrombotic Thrombocytopenic 51
Moschcowitz's Syndrome 12
Moschkowitz Disease 24
Ttp 24

Classifications:



Summaries for Thrombotic Thrombocytopenic Purpura

PubMed Health : 59
About thrombotic thrombocytopenic purpura: Thrombotic thrombocytopenic purpura (TTP) is a rare blood disorder. In TTP, blood clots form in small blood vessels throughout the body.The clots can limit or block the flow of oxygen-rich blood to the body's organs, such as the brain, kidneys, and heart. As a result, serious health problems can develop.The increased clotting that occurs in TTP also uses up platelets (PLATE-lets) in the blood. Platelets are blood cell fragments that help form blood clots. These cell fragments stick together to seal small cuts and breaks on blood vessel walls and stop bleeding.With fewer platelets available in the blood, bleeding problems can occur. People who have TTP may bleed inside their bodies, underneath the skin, or from the surface of the skin. When cut or injured, they also may bleed longer than normal."Thrombotic" (throm-BOT-ik) refers to the blood clots that form. "Thrombocytopenic" (throm-bo-cy-toe-PEE-nick) means the blood has a lower than normal number of platelets. "Purpura" (PURR-purr-ah) refers to purple bruises caused by bleeding under the skin.Bleeding under the skin also can cause tiny red or purple dots on the skin. These pinpoint-sized dots are called petechiae (peh-TEE-kee-ay). Petechiae may look like a rash.

MalaCards based summary : Thrombotic Thrombocytopenic Purpura, also known as purpura, thrombotic thrombocytopenic, is related to thrombotic thrombocytopenic purpura, congenital and purpura, and has symptoms including proteinuria, hematuria and seizures. An important gene associated with Thrombotic Thrombocytopenic Purpura is ADAMTS13 (ADAM Metallopeptidase With Thrombospondin Type 1 Motif 13), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Cell surface interactions at the vascular wall. The drugs rituximab and Antirheumatic Agents have been mentioned in the context of this disorder. Affiliated tissues include kidney, brain and heart, and related phenotypes are cardiovascular system and hematopoietic system

Genetics Home Reference : 24 Thrombotic thrombocytopenic purpura is a rare disorder that causes blood clots (thrombi) to form in small blood vessels throughout the body. These clots can cause serious medical problems if they block vessels and restrict blood flow to organs such as the brain, kidneys, and heart. Resulting complications can include neurological problems (such as personality changes, headaches, confusion, and slurred speech), fever, abnormal kidney function, abdominal pain, and heart problems.

Wikipedia : 72 Thrombotic thrombocytopenic purpura (TTP) is a rare disorder of the blood-coagulation system, causing... more...

Related Diseases for Thrombotic Thrombocytopenic Purpura

Diseases in the Thrombotic Thrombocytopenic Purpura family:

Thrombotic Thrombocytopenic Purpura, Congenital Thrombotic Thrombocytopenic Purpura, Acquired

Diseases related to Thrombotic Thrombocytopenic Purpura via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 234)
# Related Disease Score Top Affiliating Genes
1 thrombotic thrombocytopenic purpura, congenital 34.8 ADAMTS13 CFH
2 purpura 31.1 ADAMTS13 APOH F3 THBD VWF
3 hemolytic uremic syndrome, atypical 1 30.7 CFH THBD
4 disseminated intravascular coagulation 30.6 ADAMTS13 F3 THBD
5 hemolytic-uremic syndrome 30.4 ADAMTS13 CD46 CFH THBD VWF
6 spotted fever 30.3 THBD VWF
7 acute myocardial infarction 30.2 F3 SELP VWF
8 heparin-induced thrombocytopenia 30.2 F3 SELP
9 coronary thrombosis 30.1 F3 VWF
10 polyarteritis nodosa 30.1 APOH SELE
11 thrombocytopenia 30.0 ADAMTS13 APOH F3 THBD
12 retinal vascular occlusion 30.0 APOH SELP
13 buerger disease 29.9 APOH SELE
14 afibrinogenemia 29.8 CD46 F3 VWF
15 myocardial infarction 29.7 ADAMTS13 F3 SELP THBD VWF
16 membranoproliferative glomerulonephritis 29.7 CD46 CFH
17 protein s deficiency 29.7 APOH F3
18 hemorrhagic disease 29.6 ADAMTS13 F3 THBD VWF
19 von willebrand's disease 29.6 ADAMTS13 F3 SELP VWF
20 vasculitis 29.6 APOH SELE THBD VWF
21 essential thrombocythemia 29.5 F3 SELP THBD VWF
22 systemic lupus erythematosus 29.4 ADAMTS13 APOH F3 SELE THBD VWF
23 thrombosis 29.3 APOH F3 SELP THBD VWF
24 thrombophilia 29.2 APOH F3 THBD VWF
25 antiphospholipid syndrome 28.9 ADAMTS13 APOH F3 SELE SELP THBD
26 vascular disease 28.4 APOH F3 SELE SELP THBD VWF
27 pre-eclampsia 28.3 APOH F3 SELE SELP THBD VWF
28 hellp syndrome 28.3 ADAMTS13 APOH CD46 CFH F3 THBD
29 thrombotic thrombocytopenic purpura, acquired 12.8
30 lupus erythematosus 10.5
31 bombay phenotype 10.5 ADAMTS13 VWF
32 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.5
33 unilateral absence of a pulmonary artery 10.5 THBD VWF
34 autoimmune disease of blood 10.4 ADAMTS13 VWF
35 pancreatitis 10.4
36 eisenmenger syndrome 10.4 THBD VWF
37 platelet aggregation, spontaneous 10.4 SELP VWF
38 retinitis 10.4
39 endotheliitis 10.4
40 boutonneuse fever 10.3 SELE THBD
41 connective tissue disease 10.3
42 chronic active epstein-barr virus infection 10.3 SELE THBD
43 acute pancreatitis 10.3
44 von willebrand disease, type 1 10.3 F3 VWF
45 angina pectoris 10.3 F3 VWF
46 korean hemorrhagic fever 10.3 F3 VWF
47 hepatitis 10.3
48 adult-onset still's disease 10.3
49 mixed connective tissue disease 10.3
50 inherited blood coagulation disease 10.3 F3 VWF

Graphical network of the top 20 diseases related to Thrombotic Thrombocytopenic Purpura:



Diseases related to Thrombotic Thrombocytopenic Purpura

Symptoms & Phenotypes for Thrombotic Thrombocytopenic Purpura

Human phenotypes related to Thrombotic Thrombocytopenic Purpura:

31 (show all 20)
# Description HPO Frequency HPO Source Accession
1 proteinuria 31 occasional (7.5%) HP:0000093
2 hematuria 31 occasional (7.5%) HP:0000790
3 seizures 31 frequent (33%) HP:0001250
4 coma 31 frequent (33%) HP:0001259
5 confusion 31 frequent (33%) HP:0001289
6 stroke 31 frequent (33%) HP:0001297
7 myocardial infarction 31 occasional (7.5%) HP:0001658
8 thrombocytopenia 31 hallmark (90%) HP:0001873
9 acute kidney injury 31 very rare (1%) HP:0001919
10 reticulocytosis 31 hallmark (90%) HP:0001923
11 microangiopathic hemolytic anemia 31 hallmark (90%) HP:0001937
12 fever 31 occasional (7.5%) HP:0001945
13 diarrhea 31 frequent (33%) HP:0002014
14 abdominal pain 31 frequent (33%) HP:0002027
15 dyspnea 31 hallmark (90%) HP:0002094
16 headache 31 frequent (33%) HP:0002315
17 generalized muscle weakness 31 hallmark (90%) HP:0003324
18 arrhythmia 31 occasional (7.5%) HP:0011675
19 decreased serum creatinine 31 very rare (1%) HP:0012101
20 abnormal lactate dehydrogenase activity 31 frequent (33%) HP:0045040

UMLS symptoms related to Thrombotic Thrombocytopenic Purpura:


tremor, fever

MGI Mouse Phenotypes related to Thrombotic Thrombocytopenic Purpura:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.97 CFH THBS1 VWF F3 SELE SELP
2 hematopoietic system MP:0005397 9.97 CFH THBS1 F3 VWF SELE ADAMTS13
3 homeostasis/metabolism MP:0005376 9.91 CFH THBS1 VWF F3 SELE ADAMTS13
4 immune system MP:0005387 9.81 CFH THBS1 F3 VWF SELE ADAMTS13
5 mortality/aging MP:0010768 9.65 CFH THBS1 F3 VWF SELE ADAMTS13
6 vision/eye MP:0005391 9.17 CFH THBS1 F3 SELE ADAMTS13 SELP

Drugs & Therapeutics for Thrombotic Thrombocytopenic Purpura

PubMedHealth treatment related to Thrombotic Thrombocytopenic Purpura: 59

Thrombotic thrombocytopenic purpura (TTP) can be fatal or cause lasting damage, such as brain damage or a stroke, if it's not treated right away.In most cases, TTP occurs suddenly and lasts for days or weeks, but it can go on for months. Relapses (flareups) can occur in up to 60 percent of people who have acquired TTP. Flareups also occur in most people who have inherited TTP.Plasma treatments are the most common way to treat TTP. Other treatments include medicines and surgery. Treatments are done in a hospital.

Drugs for Thrombotic Thrombocytopenic Purpura (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 84)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1 174722-31-7 10201696
2 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
3
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
4
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2 22916-47-8 4189
5
Tacrolimus Approved, Investigational Phase 2, Phase 3 104987-11-3 445643 439492
6
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
7
Everolimus Approved Phase 2, Phase 3 159351-69-6 6442177
8
Sirolimus Approved, Investigational Phase 2, Phase 3 53123-88-9 46835353 6436030 5284616
9 Antifungal Agents Phase 3,Phase 2
10 Anti-Infective Agents Phase 3,Phase 2
11 Anti-Inflammatory Agents Phase 3,Phase 2
12 Antineoplastic Agents, Hormonal Phase 3,Phase 2
13 Calcineurin Inhibitors Phase 3,Phase 2
14 Cyclosporins Phase 3
15 Dermatologic Agents Phase 3
16 glucocorticoids Phase 3,Phase 2
17 Hormone Antagonists Phase 3,Phase 2
18 Hormones Phase 3,Phase 2
19 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
20 Immunosuppressive Agents Phase 3,Phase 2
21 Anti-Bacterial Agents Phase 2, Phase 3
22 Antibiotics, Antitubercular Phase 2, Phase 3
23 Peripheral Nervous System Agents Phase 3,Phase 2
24 Analgesics Phase 3
25 Anesthetics Phase 3
26 Anti-Arrhythmia Agents Phase 3
27 Anticonvulsants Phase 3
28 calcium channel blockers Phase 3
29 Calcium, Dietary Phase 3
30 Central Nervous System Depressants Phase 3
31 Tocolytic Agents Phase 3
32
Acetaminophen Approved Phase 2 103-90-2 1983
33
Diphenhydramine Approved, Investigational Phase 2 58-73-1, 147-24-0 3100
34
Promethazine Approved, Investigational Phase 2 60-87-7 4927
35
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
36
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
37
Danazol Approved Phase 2 17230-88-5 28417
38
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
39 Ixazomib Approved, Investigational Phase 2 1072833-77-2
40
Lenalidomide Approved Phase 2 191732-72-6 216326
41
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
42
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
43
Glycine Approved, Nutraceutical, Vet_approved Phase 2 56-40-6 750
44
Camptothecin Experimental Phase 2 7689-03-4
45 Pharmaceutical Solutions Phase 2
46 Angiogenesis Inhibitors Phase 2
47 Angiogenesis Modulating Agents Phase 2
48 Antineoplastic Agents, Phytogenic Phase 2
49 topoisomerase I inhibitors Phase 2
50 Topoisomerase Inhibitors Phase 2

Interventional clinical trials:

(show all 37)

# Name Status NCT ID Phase Drugs
1 Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab Completed NCT00820469 Phase 4 Rituximab 375;rituximab 1000
2 Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic Purpura Withdrawn NCT01754545 Phase 4 Octaplas infusion and placebo (group 1);Octaplas infusion and placebo (group 2)
3 Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP) Completed NCT00713193 Phase 3 Cyclosporine;Prednisone
4 Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura Completed NCT02553317 Phase 3
5 A Phase 3, Randomized, Controlled Study of Prophylactic and On-demand Treatment of cTTP With BAX 930 (rADAMTS13) Active, not recruiting NCT03393975 Phase 3
6 Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES) Active, not recruiting NCT02878603 Phase 3
7 Magnesium Sulfate in Thrombotic Thrombocytopenic Purpura in Intensive Care Not yet recruiting NCT03237819 Phase 3 Sulfate, Magnesium;Placebo - Concentrate
8 Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP) Terminated NCT00411801 Phase 3
9 Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP) Terminated NCT00799773 Phase 3 Rituximab;Corticosteroids
10 Prevention of the Graft-Versus-Host-Disease in Patients After Stem Cell Transplantation With Tacrolimus and Everolimus Terminated NCT00117702 Phase 2, Phase 3 Tacrolimus;Everolimus
11 The Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP) Unknown status NCT00937131 Phase 2 Rituximab
12 Rituximab in Patients With Relapsed or Refractory TTP-HUS Unknown status NCT00531089 Phase 2 Rituximab
13 Study to Assess Efficacy and Safety of Anti-von Willebrand Factor Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (TTP) Completed NCT01151423 Phase 2
14 Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura Completed NCT00907751 Phase 2 rituximab
15 Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas Completed NCT00412542 Phase 2 Thalidomide;CPT-11
16 An Open-label Safety Study of S-888711 Completed NCT01129024 Phase 2 0.5 mg of S-888711
17 Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP) Recruiting NCT00953771 Phase 2 Danazol
18 Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura Recruiting NCT01554514 Phase 2
19 Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement Recruiting NCT02765854 Phase 2 Dexamethasone;Ixazomib;Lenalidomide
20 A Single-center Clinical Trial of Bortezomib in Management of Immune Thrombocytopenia (ITP) Not yet recruiting NCT03013114 Phase 2 Bortezomib
21 IdeS in Asymptomatic Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Patients Terminated NCT02854059 Phase 1, Phase 2
22 Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy Terminated NCT00726544 Phase 2 ARC 1779 Placebo;ARC1779 Injection;ARC1779 Injection;ARC1779 Injection
23 A Study to Investigate the Efficacy and Safety of S-888711 Tablets Administered to Adult Subjects With Immune Thrombocytopenia (ITP) Terminated NCT01054443 Phase 2 placebo to S-888711;S-888711;S-888711;S-888711
24 Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura Withdrawn NCT00251277 Phase 1, Phase 2 Rituximab
25 Phase 1 Dose Escalation, Single Dose Study to Assess Safety and Pharmacokinetics of BAX930 in Hereditary Thrombotic Thrombocytopenic Purpura (TTP) Completed NCT02216084 Phase 1 Recombinant ADAMTS13
26 Influence of Extracorporeal Circulation During Cardiac Surgery on the Development of Postoperative Thrombotic Thrombocytopenic Purpura (TTP) Unknown status NCT01300117
27 Levels of Von Willebrand Factor Multimers and VWF-Cleaving Protease (ADAMTS-13) in Preterm and Neonate Unknown status NCT00701610
28 ADAMTS13 in Thrombotic Thrombocytopenic Purpura Completed NCT00426686
29 Early Predictive Factors of Cardiac and Cerebral Involvement in TMA Completed NCT02134171
30 Promising Bimarker Prediction of Outcome of HELLP Syndrome. Completed NCT03246542
31 Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX Completed NCT00360685 Tac+MTX;TAC + MMF
32 Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome) Recruiting NCT01257269
33 Octaplas Adult TTP Trial Recruiting NCT01938404 Standard Plasma
34 Observational Study of the Use of octaplasLG®. Recruiting NCT03369314 octaplasLG®
35 A Prospective Study on the Long-Term Vascular Burden in TTP Patients Recruiting NCT03187652
36 The Role of Microparticles as a Biomarker Enrolling by invitation NCT02626663
37 International Registry and Biorepository for TMA(Thrombotic Microangiopathy) Terminated NCT00593229

Search NIH Clinical Center for Thrombotic Thrombocytopenic Purpura

Cochrane evidence based reviews: purpura, thrombotic thrombocytopenic

Genetic Tests for Thrombotic Thrombocytopenic Purpura

Anatomical Context for Thrombotic Thrombocytopenic Purpura

MalaCards organs/tissues related to Thrombotic Thrombocytopenic Purpura:

38
Kidney, Brain, Heart, Skin, Liver, Endothelial, Testes

Publications for Thrombotic Thrombocytopenic Purpura

Articles related to Thrombotic Thrombocytopenic Purpura:

(show top 50) (show all 902)
# Title Authors Year
1
Neuro-Behcet's disease in a patient with thrombotic thrombocytopenic purpura. ( 29444324 )
2018
2
Insights into 3D Structure of ADAMTS13: A Stepping Stone towards Novel Therapeutic Treatment of Thrombotic Thrombocytopenic Purpura. ( 29304523 )
2018
3
Changes in plasma von Willebrand factor and von Willebrand factor cleaving protease in thrombotic thrombocytopenic purpura: A case report. ( 29250148 )
2018
4
Inherited thrombotic thrombocytopenic purpura mimicking immune thrombocytopenic purpura during pregnancy: a case report. ( 29357939 )
2018
5
Large vessel stroke as initial presentation of thrombotic thrombocytopenic purpura. ( 29437728 )
2018
6
Intravenous immunoglobulin as salvage therapy for refractory thrombotic thrombocytopenic purpura. ( 29247542 )
2018
7
An open conformation of ADAMTS-13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura. ( 29222940 )
2018
8
Pathophysiology of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. ( 29356300 )
2018
9
No major differences in outcomes between the initial and relapse episodes in patients with thrombotic thrombocytopenic purpura: The experience from the Ohio State University Registry. ( 29226481 )
2018
10
Successful kidney transplantation in a patient with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome). ( 28940540 )
2017
11
Autoimmune Thrombotic Thrombocytopenic Purpura: Two Rare Cases Associated with Juvenile Idiopathic Arthritis and Multiple Sclerosis. ( 28791286 )
2017
12
Rare Presentation of Refractory Thrombotic Thrombocytopenic Purpura: Jejunal Stricture. ( 29340125 )
2017
13
Siblings with congenital thrombotic thrombocytopenic purpura. ( 28883277 )
2017
14
Does Bernard-Soulier syndrome protect against thrombotic thrombocytopenic purpura? ( 28653757 )
2017
15
Acquired thrombotic thrombocytopenic purpura and pregnancy: More light than shade but controversies remain. ( 28697902 )
2017
16
Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens. ( 29296757 )
2017
17
Diagnosis of thrombotic thrombocytopenic purpura among patients with ADAMTS13 Activity 10%-20. ( 28815685 )
2017
18
Dengue and Thrombotic Thrombocytopenic Purpura. ( 28904490 )
2017
19
Chikungunya Fever Presenting as Life Threatening Thrombotic Thrombocytopenic Purpura. ( 28792176 )
2017
20
A novel homozygous frameshift mutation in Exon 7 of the ADAMTS13 gene in a patient with congenital thrombotic thrombocytopenic purpura from India: a case report. ( 28833243 )
2017
21
Long-term Kidney Outcomes in Patients With Acquired Thrombotic Thrombocytopenic Purpura. ( 29270517 )
2017
22
Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics. ( 28662310 )
2017
23
Management of thrombotic thrombocytopenic purpura without plasma exchange: the Jehovah's Witness experience. ( 29296863 )
2017
24
Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura. ( 29296854 )
2017
25
Thrombotic Thrombocytopenic Purpura or Disseminated Intravascular Coagulation? ( 28904488 )
2017
26
Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. ( 29296701 )
2017
27
Therapeutic plasma exchange for thrombotic thrombocytopenic purpura with refractory thrombocytopenia. ( 29270999 )
2017
28
Dynamic changes in absolute immature platelet count suggest the presence of a coexisting immune process in the setting of thrombotic thrombocytopenic purpura. ( 28083876 )
2017
29
Pseudo-thrombotic thrombocytopenic purpura presenting as multi-organ dysfunction syndrome: A rare complication of pernicious anemia. ( 28620491 )
2017
30
Thrombotic Thrombocytopenic Purpura ( 29261870 )
2017
31
A case report of iatrogenic cutaneous Kaposi sarcoma due to rituximab therapy for thrombotic thrombocytopenic purpura. ( 27885868 )
2017
32
Development of Thrombotic Thrombocytopenic Purpura in Association With the Monoclonal Antibody, Golimumab, Used to Treat Rheumatoid Arthritis, in a Case With Literature Review. ( 29293116 )
2017
33
Novel therapeutic approaches for thrombotic thrombocytopenic purpura. ( 28759473 )
2017
34
Recombinant ADAMTS 13 in thrombotic thrombocytopenic purpura. ( 29344548 )
2017
35
Using plasma exchange to successfully manage thyrotoxicosis in a patient with possible antithyroid drug-related thrombotic thrombocytopenic purpura. ( 28858843 )
2017
36
The role of human leukocyte antigen DRB1-DQB1 haplotypes in the susceptibility to acquired idiopathic thrombotic thrombocytopenic purpura. ( 27866840 )
2017
37
Development of systemic lupus erythematosus 5 years after onset of thrombotic thrombocytopenic purpura. ( 28707764 )
2017
38
Rituximab for thrombotic thrombocytopenic purpura: lessons from the STAR trial. ( 28671324 )
2017
39
Lacosamide-Induced Thrombotic Thrombocytopenic Purpura. ( 28874058 )
2017
40
Acquired Thrombotic Thrombocytopenic Purpura in a Patient with Pernicious Anemia. ( 28473932 )
2017
41
ASFA Category IV becomes Category I: Idiopathic thrombotic thrombocytopenic purpura in a patient with presumed gemcitabine-induced thrombotic microangiopathy. ( 28940604 )
2017
42
Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura. ( 28576877 )
2017
43
Proteolytic inactivation of ADAMTS13 by plasmin in human plasma: risk of thrombotic thrombocytopenic purpura. ( 29228282 )
2017
44
ADAMTS13 test and/or PLASMIC clinical score in management of acquired thrombotic thrombocytopenic purpura: a cost-effective analysis. ( 28646526 )
2017
45
Acute disseminated melioidosis giving rise to pneumonia and renal abscesses complicated with thrombotic thrombocytopenic purpura in a post partum woman: a case report. ( 29187254 )
2017
46
Thrombotic thrombocytopenic purpura. ( 28416507 )
2017
47
EB virus reactivation triggers thrombotic thrombocytopenic purpura in a healthy adult. ( 28702343 )
2017
48
Pathophysiology of thrombotic thrombocytopenic purpura. ( 28768626 )
2017
49
Acute pancreatitis-induced thrombotic thrombocytopenic purpura with recurrent acute pancreatitis. ( 26905311 )
2016
50
When the picture is fragmented: Vitamin B12 deficiency masquerading as thrombotic thrombocytopenic purpura. ( 27308258 )
2016

Variations for Thrombotic Thrombocytopenic Purpura

Expression for Thrombotic Thrombocytopenic Purpura

Search GEO for disease gene expression data for Thrombotic Thrombocytopenic Purpura.

Pathways for Thrombotic Thrombocytopenic Purpura

GO Terms for Thrombotic Thrombocytopenic Purpura

Cellular components related to Thrombotic Thrombocytopenic Purpura according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 ADAMTS13 APOH CFH F3 SELE SELP
2 extracellular matrix GO:0031012 9.46 APOH F3 THBS1 VWF
3 platelet alpha granule GO:0031091 9.26 THBS1 VWF
4 cell surface GO:0009986 9.1 ADAMTS13 APOH CD46 F3 THBD THBS1

Biological processes related to Thrombotic Thrombocytopenic Purpura according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 cell adhesion GO:0007155 9.86 SELE SELP THBS1 VWF
2 leukocyte migration GO:0050900 9.72 SELE SELP THBD
3 response to lipopolysaccharide GO:0032496 9.71 SELE SELP THBD
4 negative regulation of endothelial cell proliferation GO:0001937 9.57 APOH THBS1
5 blood coagulation GO:0007596 9.56 ADAMTS13 F3 THBD VWF
6 leukocyte cell-cell adhesion GO:0007159 9.52 SELE SELP
7 response to tumor necrosis factor GO:0034612 9.51 ADAMTS13 SELE
8 negative regulation of endothelial cell migration GO:0010596 9.49 APOH THBS1
9 blood coagulation, intrinsic pathway GO:0007597 9.48 APOH VWF
10 leukocyte tethering or rolling GO:0050901 9.46 SELE SELP
11 platelet degranulation GO:0002576 9.46 APOH SELP THBS1 VWF
12 negative regulation of blood coagulation GO:0030195 9.43 APOH THBD
13 protein O-linked fucosylation GO:0036066 9.4 ADAMTS13 THBS1
14 positive regulation of blood coagulation GO:0030194 9.37 APOH THBS1
15 positive regulation of transforming growth factor beta production GO:0071636 9.32 CD46 THBS1
16 negative regulation of fibrinolysis GO:0051918 9.13 APOH THBD THBS1
17 hemostasis GO:0007599 8.92 ADAMTS13 F3 THBD VWF

Molecular functions related to Thrombotic Thrombocytopenic Purpura according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integrin binding GO:0005178 9.43 ADAMTS13 THBS1 VWF
2 sialic acid binding GO:0033691 9.16 SELE SELP
3 oligosaccharide binding GO:0070492 8.96 SELE SELP
4 heparin binding GO:0008201 8.92 APOH CFH SELP THBS1

Sources for Thrombotic Thrombocytopenic Purpura

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....